Ticker

Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) and Prime Medicine (NYSE: PRME - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Profitability This table compares Eloxx Pharmaceuticals and Prime

Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Profitability This table compares Eloxx Pharmaceuticals and Finch Therapeutics Group's

Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Eloxx Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals"s revenue, earnings per share and

Valuation and Earnings This table compares Eloxx Pharmaceuticals and Cortexyme"s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eloxx Pharmaceuticals N/A N/A -$36.06 million ($9.07) 0.00 Cortexyme N/A N/A -$89.94 million ($2.97) -1.20 Cortexyme is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals,

Insider and Institutional Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 27.9% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money